Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

"Company†) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e. LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the ...